This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stiborová, M. Articles by Frei, E. Search for Related Content PubMed PubMed Citation Articles by Stiborová, M. Articles by Frei, E.

The Anticancer Drug Ellipticine Forms Covalent DNA Adducts, Mediated by Human Cytochromes P450, through Metabolism to 13-Hydroxyellipticine and Ellipticine N²-Oxide

Marie Stiborová¹, Jan Sejbal², Lucie Boek-Dohalská¹, Dagmar Aimová¹, Jitka Poljaková¹, Kristina Forsterová¹, Martina Rupertová¹, Jií Wiesner¹, Jií Hudeek¹, Manfred Wiessler³ and Eva Frei³

Departments of ¹ Biochemistry and ² Organic Chemistry, Faculty of Science, Charles University, Prague, Czech Republic; and ³ Division of Molecular Toxicology, German Cancer Research Center, Heidelberg, Germany

Ellipticine is an antineoplastic agent, the mode of action of which is considered to be based on DNA intercalation and inhibition of topoisomerase II. We found that ellipticine also forms the cytochrome P450 (CYP)-mediated covalent DNA adducts. We now identified the ellipticine metabolites formed by human CYPs and elucidated the metabolites responsible for DNA binding. The 7-hydroxyellipticine, 9-hydroxyellipticine, 12-hydroxyellipticine, 13-hydroxyellipticine, and ellipticine N²-oxide are generated by hepatic microsomes from eight human donors. The role of specific CYPs in the oxidation of ellipticine and the role of the ellipticine metabolites in the formation of DNA adducts were investigated by correlating the levels of metabolites formed in each microsomal sample with CYP activities and with the levels of the ellipticine-derived deoxyguanosine adducts in DNA. On the basis of this analysis, formation of 9-hydroxyellipticine and 7-hydroxyellipticine was attributable to CYP1A1/2, whereas production of 13-hydroxyellipticine and ellipticine N²-oxide, the metabolites responsible for formation of two major DNA adducts, was attributable to CYP3A4. Using recombinant human enzymes, oxidation of ellipticine to 9-hydroxyellipticine and 7-hydroxyellipticine by CYP1A1/2 and to 13-hydroxyellipticine and N²-oxide by CYP3A4 was corroborated. Homologue modeling and docking of ellipticine to the CYP3A4 active center was used to explain the predominance of ellipticine oxidation by CYP3A4 to 13-hydroxyellipticine and N²-oxide.

This article has been cited by other articles:

				V. M. Lakshmi, F.-F. Hsu, and T. V. Zenser Identification of New 2-Amino-3-methylimidazo[4,5-f]quinoline Urinary Metabolites from {beta}-Naphthoflavone-Treated Mice Drug Metab. Dispos., August 1, 2009; 37(8): 1690 - 1697. [Abstract] [Full Text] [PDF]

				V. M. Arlt, M. Stiborova, C. J. Henderson, M. Thiemann, E. Frei, D. Aimova, R. Singh, G. Gamboa da Costa, O. J. Schmitz, P. B. Farmer, et al. Metabolic activation of benzo[a]pyrene in vitro by hepatic cytochrome P450 contrasts with detoxification in vivo: experiments with hepatic cytochrome P450 reductase null mice Carcinogenesis, March 1, 2008; 29(3): 656 - 665. [Abstract] [Full Text] [PDF]

				E. Tian, T. H. Landowski, O. W. Stephens, S. Yaccoby, B. Barlogie, and J. D. Shaughnessy Jr. Ellipticine derivative NSC 338258 represents a potential new antineoplastic agent for the treatment of multiple myeloma Mol. Cancer Ther., March 1, 2008; 7(3): 500 - 509. [Abstract] [Full Text] [PDF]

				D. Aimova, L. Svobodova, V. Kotrbova, B. Mrazova, P. Hodek, J. Hudecek, R. Vaclavikova, E. Frei, and M. Stiborova The Anticancer Drug Ellipticine Is a Potent Inducer of Rat Cytochromes P450 1A1 and 1A2, Thereby Modulating Its Own Metabolism Drug Metab. Dispos., October 1, 2007; 35(10): 1926 - 1934. [Abstract] [Full Text] [PDF]

				V. M. Arlt, E. Frei, and H. H. Schmeiser ECNIS-sponsored workshop on biomarkers of exposure and cancer risk: DNA damage and DNA adduct detection and 6th GUM-32P-postlabelling workshop, German Cancer Research Center, Heidelberg, Germany, 29-30 September 2006 Mutagenesis, January 1, 2007; 22(1): 83 - 88. [Abstract] [Full Text] [PDF]